Publications
378 publications
- Date
- Relevance
-
Appendix to guideline for cost-effectiveness models in R - packages and versions
Appendix to guideline for cost-effectiveness models in R - packages and versions.
-
Guideline for building cost-effectiveness models in R
Guideline for building cost-effectiveness models in R.
-
Package advice atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)
The National Health Care Institute advises the Minister to include atidarsagene autotemcel (Libmeldy®) in the basic health care ...
-
Package advice brexucabtagene autoleucel (Tecartus®) refractory mantle cell lymphoma
The National Health Care Institute advises the Minister not to include brexucabtagene autoleucel (Tecartus®) in the basic health ...
-
Package advice sacituzumab govitecan (Trodelvy®) for the treatment of inoperable or metastasized triple-negative breast cancer
The National Health Care Institute advises the Minister to include sacituzumab govitecan (Trodelvy®) in the basic health care ...
-
GVS advice testosterone undecanoate (Nebido®)
The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...
-
Package advice risdiplam (Evrysdi®) for the treatment of 5q spinal muscular atrophy (SMA)
The National Health Care Institute advises the Minister to include risdiplam (Evrysdi®) in the health insurance package for the ...
-
GVS advice setmelanotide (Imcivree®)
The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...
-
GVS advice metreleptin (Myalepta®)
The National Health Care Institute advises the Minister to include metreleptin (Myalepta®) in List 1B of the GVS. Metreleptin is ...
-
Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors
The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...